High drug loading pharmaceutical compositions
A pharmaceutical composition of high drug loading comprising an active pharmaceutical ingredient (API) and pharmaceutical acceptable additives, which include glass-solution forming additive and/or eutectic-mixture forming additive, is provided. The composition is dispersed uniformly to form a hybrid solid dispersion consisting of crystalline-suspension, glass-solution and/or eutectic-mixture, where the crystalline API is uniformly distributed in the hybrid solid dispersion and exists in nano/micro particle size range. The amorphous API, when present, is uniformly distributed in the hybrid solid dispersion. The API may exist in different chemical and/or physical forms. The API is present in an amount of from more than about 50% wt/wt to about 90% wt/wt with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives. At least about 50% wt/wt of the API is dispersed in the crystalline-suspension and at least about 5% wt/wt of the API is dispersed in the glass-solution and/or eutectic-mixture. The pharmaceutical composition offers excellent dissolution rate, superior chemical and physical stability, and minimum drug-drug/drug-excipient incompatibility. The composition is beneficial for reducing the overall tablet/capsule size for low water-soluble drugs requiring high drug loading or dosage, including combination drugs.
1. A pharmaceutical composition comprising:
an active pharmaceutical ingredient; and
pharmaceutically acceptable glass-solution forming additives, and/or
pharmaceutically acceptable eutectic-mixture forming additives,
wherein the active pharmaceutical ingredient and the pharmaceutically acceptable additives are present in the form of a hybrid solid dispersion consisting of a uniformly distributed solid dispersion of:
a crystalline-suspension; and
a glass-solution and/or a eutectic-mixture,
wherein the active pharmaceutical ingredient is present in an amount of from more than 50% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition,
wherein about 50% w/w to about 95% w/w of the active pharmaceutical ingredient is dispersed in the crystalline-suspension and the remaining active pharmaceutical ingredient is dispersed in the glass-solution and/or the eutectic-mixture,
wherein crystalline active pharmaceutical ingredient exists in a nano/micro particle size range and is uniformly distributed in the hybrid solid dispersion, and
wherein amorphous active pharmaceutical ingredient, when present, is uniformly distributed in the hybrid solid dispersion,
wherein the composition is prepared by a process comprising:
i) generating a uniform suspension of nano/micro size particles of the active pharmaceutical ingredient's crystals in one or more solvents containing partially dissolved active pharmaceutical ingredient and fully dissolved pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives; and
ii) evaporating the solvents from the suspension to obtain dry solid particles.
2. A pharmaceutical composition consisting essentially of:
an active pharmaceutical ingredient; and
pharmaceutically acceptable glass-solution forming additives, and/or
pharmaceutically acceptable eutectic-mixture forming additives,
wherein the active pharmaceutical ingredient and the pharmaceutically acceptable additives are present in the form of a hybrid solid dispersion consisting of a uniformly distributed solid dispersion of:
a crystalline-suspension; and
a glass-solution and/or a eutectic-mixture,
wherein the active pharmaceutical ingredient is present in an amount of from more than 50% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition,
wherein about 50% w/w to about 95% w/w of the active pharmaceutical ingredient is dispersed in the crystalline-suspension and the remaining active pharmaceutical ingredient is dispersed in the glass-solution and/or the eutectic-mixture,
wherein crystalline active pharmaceutical ingredient exists in a nano/micro particle size range and is uniformly distributed in the hybrid solid dispersion, and wherein amorphous active pharmaceutical ingredient, when present, is uniformly distributed in the hybrid solid dispersion,
wherein the composition is prepared by a process comprising:
i) generating a uniform suspension of nano/micro size particles of the active pharmaceutical ingredient's crystals in one or more solvents containing partially dissolved active pharmaceutical ingredient and fully dissolved pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives; and
ii) evaporating the solvents from the suspension to obtain dry solid particles.
3. The composition according to claim 1 , wherein about 50% w/w to about 90% w/w of the active pharmaceutical ingredient is dispersed in the crystalline-suspension and the remaining active pharmaceutical ingredient is dispersed in the glass-solution and/or the eutectic-mixture.
4. The composition according to claim 1 , wherein the active pharmaceutical ingredient exists in different chemical and/or physical forms in the crystalline-suspension, the glass-solution and/or the eutectic-mixture.
5. The composition according to claim 1 , wherein the active pharmaceutical ingredient is ibuprofen, and/or ibuprofen sodium.
6. The composition according to claim 1 , wherein the composition further comprises one or more additional active pharmaceutical ingredients.
7. A process for the preparation of a pharmaceutical composition comprising:
an active pharmaceutical ingredient; and
pharmaceutically acceptable glass-solution forming additives, and/or
pharmaceutically acceptable eutectic-mixture forming additives,
wherein the active pharmaceutical ingredient and the pharmaceutically acceptable additives are present in the form of a hybrid solid dispersion consisting of a uniformly distributed solid dispersion of:
a crystalline-suspension; and
a glass-solution and/or a eutectic-mixture,
wherein the active pharmaceutical ingredient is present in an amount of from more than 50% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition,
wherein about 50% w/w to about 95% w/w of the active pharmaceutical ingredient is dispersed in the crystalline-suspension and the remaining active pharmaceutical ingredient is dispersed in the glass-solution and/or the eutectic-mixture,
wherein crystalline active pharmaceutical ingredient exists in a nano/micro particle size range and is uniformly distributed in the hybrid solid dispersion, and
wherein amorphous active pharmaceutical ingredient, when present, is uniformly distributed in the hybrid solid dispersion,
wherein the process comprises:
i) generating a uniform suspension of nano/micro size particles of the active pharmaceutical ingredient's crystals in one or more solvents containing partially dissolved active pharmaceutical ingredient and fully dissolved pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives; and
ii) evaporating the solvents from the suspension to obtain dry solid particles,
wherein the active pharmaceutical ingredient is present in an amount of from more than 50% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives, and
wherein at least about 50% w/w of the active pharmaceutical ingredient is undissolved and at least about 5% w/w of the active pharmaceutical ingredient is in dissolved form.
8. The process of claim 7 , wherein the uniform suspension is generated by dissolving the active pharmaceutical ingredient in one or more solvents and then at least partially crystallizing out the active pharmaceutical ingredient from the solvents.
9. The process of claim 7 , wherein the uniform suspension is generated by mixing the active pharmaceutical ingredient crystals and one or more solvents to form a slurry or wet mass.
10. The process of claim 7 , wherein the evaporation is performed by a batch process.
11. The process of claim 7 , wherein the uniform suspension is placed in a dryer and the solvent or solvents are evaporated.
12. The process of claim 7 , wherein the evaporation is performed by a continuous process.
13. The process of claims 7 , wherein the uniform suspension is continuously fed into a dryer as a stream and the solvents are evaporated.
14. The process of claim 7 , wherein:
i) the active pharmaceutical ingredient and the glass-solution and/or eutectic-mixture forming additive(s) are dissolved in one or more solvents and rapidly mixed with an anti-solvent using an impinging jet mixer;
ii) the slurry obtained in step i) is stirred for a period of time below ambient temperature to at least partially crystallize the active pharmaceutical ingredient;
iii) the crystalline suspension obtained from step ii) is optionally warmed to re-dissolve a portion of the crystallized active pharmaceutical ingredient; and
iv) the crystalline suspension from step ii) or iii) is spray dried under vacuum at or above ambient temperature to obtain a hybrid solid dispersion.
15. The composition of claim 1 , wherein
i) the active pharmaceutical ingredient and the glass-solution and/or eutectic-mixture forming additive(s) are dissolved in one or more solvents and rapidly mixed with an anti-solvent using an impinging jet mixer;
ii) the slurry obtained in step i) is stirred below ambient temperature to at least partially crystallize the active pharmaceutical ingredient;
iii) the crystalline suspension obtained from step ii) is optionally warmed to re-dissolve a portion of the crystallized active pharmaceutical ingredient; and
iv) the crystalline suspension from step ii) or iii) is spray dried under vacuum at or above ambient temperature to obtain a hybrid solid dispersion.
16. A method for manufacturing a pharmaceutical composition having high drug loading, improved drug dissolution and stability, and reduced drug-drug or drug-excipient interaction comprising preparing a dosage form by filling the composition of claims 1 into a capsule or by compressing the composition of claim 1 into a tablet.
17. The composition according to claim 1 , wherein the active pharmaceutical ingredient is present in an amount of from about 55% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition.
18. The composition according to claim 1 , wherein the active pharmaceutical ingredient is present in an amount of from about 60% w/w to about 90 % w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition.
19. The composition according to claim 1 , wherein the active pharmaceutical ingredient is present in an amount of from about 65% w/w to about 90% w/w with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives in the pharmaceutical composition.